Edgestream Partners’s United Therapeutics UTHR Stock Holding History

Edgestream Partners’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,234	Closed	-$937K	–	1148
2025 Q3	$937K	Buy	+2,234	New	+$751K	0.03%	641
2025 Q1	–	Sell	-7,117	Closed	-$2.51M	–	1088
2024 Q4	$2.51M	Buy	7,117 +2,696	+61%	+$991K	0.11%	348
2024 Q3	$1.58M	Buy	+4,421	New	+$1.49M	0.07%	467
2024 Q2	–	Sell	-2,558	Closed	-$588K	–	1049
2024 Q1	$588K	Sell	2,558 -2,614	-51%	-$590K	0.03%	608
2023 Q4	$1.14M	Sell	5,172 -5,259	-50%	-$1.21M	0.08%	404
2023 Q3	$2.36M	Buy	10,431 +6,370	+157%	+$1.47M	0.19%	150
2023 Q2	$896K	Buy	+4,061	New	+$900K	0.08%	380
2022 Q3	–	Sell	-3,820	Closed	-$900K	–	618
2022 Q2	$900K	Buy	+3,820	New	+$777K	0.07%	341
2021 Q4	–	Sell	-4,790	Closed	-$884K	–	588
2021 Q3	$884K	Sell	4,790 -5,141	-52%	-$1.01M	0.05%	332
2021 Q2	$1.78M	Buy	+9,931	New	+$1.89M	0.11%	234

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AssetMark Inc Concord, California $49B AUM 17.78% 1-Year Est. Return

Edgestream Partners's UTHR Position: Q4 2025 in Review

Edgestream Partners sold out of United Therapeutics (UTHR) in Q4 2025, closing a stake of 2,234 shares — an estimated $937K sold.

Edgestream Partners first reported a position in UTHR in Q2 2021 and held it in 10 quarters. The position peaked at $2.51M in Q4 2024. 837 funds tracked by Wall St. Rank hold UTHR as of Q4 2025.

Edgestream Partners reported no remaining United Therapeutics position as of Q4 2025 after selling out during the quarter.
Edgestream Partners sold 2,234 United Therapeutics shares in Q4 2025, an estimated $937K.
Edgestream Partners first reported a position in United Therapeutics in Q2 2021 and held it in 10 quarters.
Edgestream Partners's United Therapeutics position peaked at $2.51M in Q4 2024.
837 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2025.

Based on Edgestream Partners's 13F filing for Q4 2025, filed 13 Feb 2026.